α₂-Antiplasmin

The main physiologic function of α2-antiplasmin is rapid inhibition of plasmin, the most potent fibrinolytic enzyme.^6-8 Through this function, α2-antiplasmin is a key player in the fibrinolytic system. The fibrinolytic system is crucial for dissolving fibrin clots, facilitating tissue repair and preventing clots from occluding vessels. There is some recent consideration that reduced fibrinolysis (due to increased α2-antiplasmin levels) is associated with an increased risk for arterial and venous thrombosis. Reduced α2-antiplasmin activity may occur in cases of hyperfibrinolysis that may be seen as a complication of disseminated intravascular coagulation (DIC) or in surgical procedures involving organs with a high content of plasminogen activators (e.g., prostate). This may also be seen in patients with acute promyelocytic leukemia, certain lung cancers, amyloidosis, abdominal aortic aneurysms, following cardiopulmonary bypass and fibrinolytic therapy. 

An α2-antiplasmin deficiency may also indicate a synthesis disorder (e.g., in severe liver cell damage) or may be seen in nephrotic syndrome. Hereditary homozygous deficiency is extremely rare and is associated with a severe bleeding disorder. Bleeding tends to be delayed. Heterozygous deficient patients may or may not exhibit a bleeding tendency. The determination of α2-antiplasmin is also indicated for additional assessment of problematic cases during fibrinolytic therapy.

Measurement of α2‑antiplasmin (α2AP), the principal physiologic inhibitor of plasmin, provides clinically useful information in the evaluation of disorders of fibrinolysis, particularly when there is discordance between bleeding symptoms and routine coagulation assays.¹ By rapidly forming plasmin–antiplasmin complexes and becoming cross‑linked to fibrin, α2AP is a major determinant of clot stability and resistance to lysis; thus, reduced activity results in accelerated fibrinolysis and a tendency toward delayed or excessive bleeding despite normal PT and aPTT, making targeted measurement essential for diagnosis.^1,2 Quantitative or functional α2AP assays are therefore primarily indicated to confirm congenital or acquired α2AP deficiency—rare conditions characterized by hyperfibrinolysis, postoperative hemorrhage or delayed wound bleeding—and may be necessary when global assays (e.g., euglobulin lysis time) suggest increased fibrinolytic activity but the etiology remains unclear.^2,3

Beyond rare inherited deficiency, α2AP measurement has broader utility in the assessment of acquired hyperfibrinolytic states, including disseminated intravascular coagulation (DIC), trauma‑associated coagulopathy and advanced liver disease, in which decreased α2AP levels may reflect either impaired hepatic synthesis or consumption during ongoing plasmin generation.^4,5 In these settings, interpretation is most informative when integrated with fibrinogen, D‑dimer, fibrin degradation products and plasminogen levels, as α2AP contributes to a more complete evaluation of the balance between coagulation and fibrinolysis rather than functioning as a standalone diagnostic marker.³ Additionally, α2AP assays may be used to monitor the effects of fibrinolytic or antifibrinolytic therapies, as circulating levels influence the efficacy of thrombolysis by directly inhibiting plasmin and modulating clot dissolution kinetics.^3,6

Emerging data also suggest a role for α2AP as a biomarker of thrombotic risk and therapeutic responsiveness. Elevated α2AP levels have been associated with reduced endogenous fibrinolysis and increased risk of venous and arterial thrombosis, including ischemic stroke, and may contribute to resistance to thrombolytic therapy by limiting plasmin activity.^1,6 Although not currently recommended as a first‑line test for thrombophilia evaluation, measurement of α2AP may provide adjunctive information in selected patients with unexplained thrombosis or suspected hypofibrinolysis, particularly in research or specialized clinical contexts.^3,6 Overall, the clinical utility of α2AP testing lies in targeted evaluation of suspected fibrinolytic disorders, clarification of bleeding phenotypes with normal routine assays and adjunctive assessment of conditions characterized by dysregulated fibrinolysis, rather than in routine hemostasis screening.